<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archivearticle1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">3906201</article-id><article-id pub-id-type="pmid">24489961</article-id><article-id pub-id-type="publisher-id">PONE-D-13-30269</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0087773</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology</subject><subj-group><subject>Genetics</subject><subj-group><subject>Genetic Mutation</subject></subj-group></subj-group><subj-group><subject>Immunology</subject><subj-group><subject>Immunity</subject><subj-group><subject>Immunity to Infections</subject></subj-group></subj-group><subj-group><subject>Genetics of the Immune System</subject><subject>Major Histocompatibility Complex</subject></subj-group></subj-group><subj-group><subject>Microbiology</subject><subj-group><subject>Immunity</subject><subj-group><subject>Adaptive Immunity</subject></subj-group></subj-group><subj-group><subject>Virology</subject><subj-group><subject>Antivirals</subject><subject>Viral Immune Evasion</subject><subject>Viral Replication</subject></subj-group></subj-group></subj-group><subj-group><subject>Population Biology</subject></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Clinical Immunology</subject><subj-group><subject>Genetics of the Immune System</subject></subj-group></subj-group><subj-group><subject>Infectious diseases</subject><subj-group><subject>Viral diseases</subject><subj-group><subject>Hepatitis</subject><subj-group><subject>Hepatitis C</subject></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Naturally Occurring Mutations in the Nonstructural Region 5B of Hepatitis C Virus (HCV) from Treatment-Na&#x000ef;ve Korean Patients Chronically Infected with HCV Genotype 1b</article-title><alt-title alt-title-type="running-head">HCV NS5B Mutations from Treatment- Na&#x000ef;ve Patients</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Dong-Won</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Seoung-Ae</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Hong</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Won</surname><given-names>You-Sub</given-names></name><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Bum-Joon</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="aff1">
<addr-line>Department of Biomedical Sciences, Microbiology and Immunology, and Liver Research Institute, College of Medicine, Seoul National University, Seoul, Korea</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Blackard</surname><given-names>Jason</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>University of Cincinnati College of Medicine, United States of America</addr-line>
</aff><author-notes><corresp id="cor1">* E-mail: <email>kbumjoon@snu.ac.kr</email></corresp><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con"><p>Conceived and designed the experiments: DWK SAL BJK. Performed the experiments: DWK. Analyzed the data: DWK BJK. Contributed reagents/materials/analysis tools: SAL HK YSW. Wrote the paper: DWK BJK.</p></fn></author-notes><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>29</day><month>1</month><year>2014</year></pub-date><volume>9</volume><issue>1</issue><elocation-id>e87773</elocation-id><history><date date-type="received"><day>23</day><month>7</month><year>2013</year></date><date date-type="accepted"><day>30</day><month>12</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; 2014 Kim et al</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Kim et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><p>The nonstructural 5B (NS5B) protein of the hepatitis C virus (HCV) with RNA-dependent RNA polymerase (RdRp) activity plays a pivotal role in viral replication. Therefore, monitoring of its naturally occurring mutations is very important for the development of antiviral therapies and vaccines. In the present study, mutations in the partial NS5B gene (492 bp) from 166 quasispecies of 15 genotype-1b (GT) treatment-na&#x000ef;ve Korean chronic patients were determined and mutation patterns and frequencies mainly focusing on the T cell epitope regions were evaluated. The mutation frequency within the CD8+ T cell epitopes was significantly higher than those outside the CD8+ T cell epitopes. Of note, the mutation frequency within predicted CD4+ T cell epitopes, a particular mutational hotspot in Korean patients was significantly higher than it was in patients from other areas, suggesting distinctive CD4+ T cell-mediated immune pressure against HCV infection in the Korean population. The mutation frequency in the NS5B region was positively correlated with patients with carrier-stage rather than progressive liver disease (chronic hepatitis, liver cirrhosis and hepatocellular carcinoma). Furthermore, the mutation frequency in four codons (Q309, A333, V338 and Q355) known to be related to the sustained virological response (SVR) and end-of treatment response (ETR) was also significantly higher in Korean patients than in patients from other areas. In conclusion, a high degree of mutation frequency in the HCV GT-1b NS5B region, particularly in the predicted CD4+ T cell epitopes, was found in Korean patients, suggesting the presence of distinctive CD4+ T cell pressure in the Korean population. This provides a likely explanation of why relatively high levels of SVR after a combined therapy of pegylated interferon (PEG-IFN) and ribavirin (RBV) in Korean chronic patients with GT-1b infections are observed.</p></abstract><funding-group><funding-statement>This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (No. 2013-005810). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="10"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>According to the WHO, 3% of the global population is infected with the hepatitis C virus (HCV), with 3&#x02013;4 million people newly infected each year <xref rid="pone.0087773-Chen1" ref-type="bibr">[1]</xref>&#x02013;<xref rid="pone.0087773-Brown1" ref-type="bibr">[4]</xref>. Most HCV infections persist, with up to 80% of all cases leading to chronic hepatitis associated with liver fibrosis, liver cirrhosis (LC) and hepatocellular carcinoma (HCC) <xref rid="pone.0087773-Seeff1" ref-type="bibr">[5]</xref>&#x02013;<xref rid="pone.0087773-Liu1" ref-type="bibr">[7]</xref>. A combinatorial treatment with pegylated interferon (PEG-IFN) and ribavirin (RBV) provides good clinical efficacy in patients infected with genotypes (GTs) 2 and 3 but is less efficacious in patients infected with the most prevalent GT-1b, thereby emphasizing the urgent need for more effective specifically targeted antiviral therapies for GT-1b <xref rid="pone.0087773-Akuta1" ref-type="bibr">[8]</xref>&#x02013;<xref rid="pone.0087773-Fried1" ref-type="bibr">[11]</xref>.</p><p>The HCV RNA-dependent RNA polymerase (RdRp) is an essential enzyme that lacks proofreading activity, thus leading to a population of distinctive but closely related viral variants, termed viral quasispecies, within an infected individual <xref rid="pone.0087773-Ferrari1" ref-type="bibr">[12]</xref>&#x02013;<xref rid="pone.0087773-Cheney1" ref-type="bibr">[14]</xref>. Monitoring of the diversity of HCV quasispecies is important for the prediction of liver disease progression as well as HCV treatment outcomes <xref rid="pone.0087773-Hamano1" ref-type="bibr">[15]</xref>&#x02013;<xref rid="pone.0087773-Blackard1" ref-type="bibr">[19]</xref>. Currently, studies regarding HCV quasispecies mainly focus on structural genomic regions; therefore, relatively limited data are available regarding nonstructural regions. Recently, variations in the nonstructural 5B (NS5B) protein, particularly in specific codons, were reported to be positively related to a sustained virological response (SVR) and end-of treatment response (ETR) of patients infected with GT-1b <xref rid="pone.0087773-Hamano1" ref-type="bibr">[15]</xref>, <xref rid="pone.0087773-Watanabe1" ref-type="bibr">[16]</xref>.</p><p>It was also reported that the SVR rate in patients with HCV GT-1b treated with PEG-IFN plus RBV are higher in Asian patients as compared with Caucasians <xref rid="pone.0087773-Missiha1" ref-type="bibr">[10]</xref>, <xref rid="pone.0087773-Yan1" ref-type="bibr">[20]</xref>. In particular, previous studies have shown that SVR rates in Korea patients infected with GT-1b range from 56% to 62% <xref rid="pone.0087773-Heo1" ref-type="bibr">[21]</xref>, <xref rid="pone.0087773-Lyoo1" ref-type="bibr">[22]</xref>. Recently, two SNPs, rs12979860 and rs8099917 of the IL28B gene, showing the strongest association with treatment response, have been reported at a high frequency in Korean patients with HCV GT-1b compared to the frequencies of other ethnic groups <xref rid="pone.0087773-Thomas1" ref-type="bibr">[23]</xref>, <xref rid="pone.0087773-Ge1" ref-type="bibr">[24]</xref>. Although prior investigations can partly explain the high SVR rates in Korean patients, other mechanisms may also contribute to this effect. In the present study, to address this issue, we investigated via quasispecies analysis the mutation frequencies and patterns in the partial NS5B from Korean patients infected with HCV GT-1b, as these are known to be related to the SVR rates,</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2a"><title>Patients and HCV RNA Extraction</title><p>Serum samples were collected from a total of 73 treatment-na&#x000ef;ve HCV-positive patients who visited Seoul National University Hospital in 2003. The clinical statuses of the HCV-positive patients were defined as carrier (C), chronic hepatitis (CH), LC or HCC. General definitions of the C and chronic liver disease types are as follows: the diagnosis of C can be made in the presence of positive anti-HCV antibodies, of a positive HCV RNA by RT-PCR, and of normal alanine aminotransferase (ALT) levels (&#x0003c;40 IU/L, assay dependent) in at least three tests carried out at least two months apart over a period of six months <xref rid="pone.0087773-Puoti1" ref-type="bibr">[25]</xref>, <xref rid="pone.0087773-Sinn1" ref-type="bibr">[26]</xref>; CH was defined as an elevation of or fluctuation in serum ALT levels over 6 months without any evidence of any other chronic liver disease <xref rid="pone.0087773-Lok1" ref-type="bibr">[27]</xref>; LC was diagnosed through evidence of clinically relevant portal hypertension (esophageal varices and/or ascites, splenomegaly with a platelet count of 100,000/mm<sup>3</sup>) <xref rid="pone.0087773-Bruix1" ref-type="bibr">[28]</xref>, ultrasonographic imaging features suggestive of liver cirrhosis <xref rid="pone.0087773-DiLelio1" ref-type="bibr">[29]</xref>, and a histological diagnosis with one of the following features: nodular regeneration, fragmentation of the biopsy with fibrosis at the margins and a wide postnecrotic collapse with an abnormal relationship between portal tracts and central veins, and evidence of active liver-cell hyperplasia <xref rid="pone.0087773-Bruguera1" ref-type="bibr">[30]</xref>. Finally, HCC in cirrhotic patients was diagnosed either through radiological criteria (focal lesion &#x0003e;2 cm with arterial hypervascularization according to two coincident imaging techniques) or through combined criteria (focal lesion &#x0003e;2 cm with arterial hypervascularization according to one imaging technique associated with AFP levels &#x0003e;400 ng/ml) <xref rid="pone.0087773-Bruix2" ref-type="bibr">[31]</xref>. HCV RNA was purified using the Viral Gene-Spin Viral DNA/RNA Kit (iNtRON Biotechnology Inc., Seongnam, Korea) according to the manufacturer's guideline. This work was approved by the institutional review board of Seoul National University Hospital (IRB No. C-1304-032-479). The experiment was mainly based on the viral RNA extracted from isolates; therefore, the research was done without informed consent and a waiver of informed consent was agreed upon by the IRB.</p></sec><sec id="s2b"><title>Quantitative PCR (qPCR) and cDNA synthesis</title><p>A qPCR method was used to analyze viral RNA with an ABI7500 system (Perkin-Elmer Applied Biosystems, Warrington, UK). The primers were designed to amplify the NS2 region and the sequences were as follows: sense primer HCVF (5&#x02032;-CGA CCA GTA CCA CCA TCC TT-3&#x02032;) and antisense primer HCVR (5&#x02032;-AGC ACC TTA CCC AGG CCT AT-3&#x02032;). For the detection of HCV RNA, the SensiFAST SYBR Lo-ROX kit (Bioline, Taunton, MA, USA) was used according to the manufacturer's instructions. Absolute quantification of extracted HCV RNA relies on the accuracy with the amount of HCV RNA standard measured with a lower limit of detection of 1,350 copies/ml (500 IU/ml) on the basis of earlier research (data not shown) <xref rid="pone.0087773-Nakatani1" ref-type="bibr">[32]</xref>, <xref rid="pone.0087773-Pawlotsky1" ref-type="bibr">[33]</xref>. Viral cDNA synthesis for Reverse-transcriptase (RT) PCR was done using the Maxime RT PreMix kit (iNtRON Biotechnology Inc., Seongnam, Korea) according to its own protocol.</p></sec><sec id="s2c"><title>Nested PCR Amplification</title><p>The nested PCR method and primer pairs to amplify GT-1 to 4 are available in the literature <xref rid="pone.0087773-vanAsten1" ref-type="bibr">[34]</xref>. Briefly, as an example of GT-1b, the first round of amplification was carried out using the sense primer A1b (O/S) (accession no. M62321, positions 8113&#x02013;8135, 5&#x02032; - CTGACRACTAGCTGYGGTAAYAC - 3&#x02032;) and the antisense primer F1b (O/A) (positions 8678&#x02013;8699, 5&#x02032; - CCTGGAGAGTAACTRTGGAGTG - 3&#x02032;). The first-round reaction was subjected to 30 cycles of amplification (30 s at 94&#x000b0;C, 30 s at 45&#x000b0;C and 50 s at 68&#x000b0;C) followed by 7 min of extension at 72&#x000b0;C. The second round of amplification was carried out using the sense primer B1b (I/S) (positions 8181&#x02013;8205, 5&#x02032; - GCTCCRGGACTGCACSATGCTCGTG - 3&#x02032;) and the antisense primer E1b (I/A) (positions 8654&#x02013;8675, 5&#x02032; - AATGCGCTRAGRCCATGGAGTC - 3&#x02032;) to amplify 495 bp of the GT-1b NS5B region. The second-round reaction was subjected to 30 cycles of amplification (30 s at 93&#x000b0;C, 30 s at 55&#x000b0;C and 1 min at 68&#x000b0;C) followed by 7 min of extension at 72&#x000b0;C.</p></sec><sec id="s2d"><title>Cloning and Sequencing Analysis</title><p>The PCR products of GT-1b were cloned using the TOPO TA Cloning kit (Invitrogen Corporation, Carlsbad, CA, USA). The NS5B regions were sequenced using the M13 primer. For each subject, 10 to 12 subclones were sequenced <xref rid="pone.0087773-Cuevas1" ref-type="bibr">[35]</xref>, <xref rid="pone.0087773-Uzicanin1" ref-type="bibr">[36]</xref>. Sequencing was conducted using the Applied Biosystems model 377 DNA automatic sequencer (Perkin-Elmer Applied Biosystems, Warrington, UK). If there were sequence variations between the clones of a sample, the dominant sequence at each position was determined as the major sequence. Nucleotides were aligned and their similarities were calculated using the multiple-alignment algorithm in Megalign (DNASTAR, Windows Version 3.12e). A mutation in this study was defined as a sequence different from the consensus sequence of 20 GT-1b reference strains obtained from the LANL HCV database (<ext-link ext-link-type="uri" xlink:href="http://hcv.lanl.gov">http://hcv.lanl.gov</ext-link>) [accession numbers AB442219, AB691953, AF165047, D11168, D13558, D16435, D50485, D85516, D90208, EU256084, EU482859, FJ478453, HQ110091, HQ912958, J238799, L02836, M58335, M96362, S62220 and X61596] <xref rid="pone.0087773-Ruhl1" ref-type="bibr">[37]</xref>. Because at aa 316 and 464, the two types of subclonal amino acids were conserved in each subject, both amino acids were considered to be a consensus sequence <xref rid="pone.0087773-Hang1" ref-type="bibr">[38]</xref>, <xref rid="pone.0087773-Ludmerer1" ref-type="bibr">[39]</xref>. For a further comparison of the analyzed sequences, 45 HCV GT-1b sequences from other countries (China: 15, Japan: 15, Switzerland: 15 and the United States: 15) were also retrieved from the LANL HCV database and relevant nucleotide positions were compared with the consensus sequence of 15 subjects.</p></sec><sec id="s2e"><title>Phylogenetic analysis</title><p>HCV GTs were confirmed by a phylogenetic analysis based on 12 reference strains representing each of the GTs of 1&#x02013;6 obtained from GenBank [accession numbers AF009606 (1a), AF064490 (5a), AY232745 (2b), D63821 (3a), D90208 (1b), DQ480515 (6a), JX961069 (2a), M58335 (1b), M67463 (1a), S62220 (1b), X61596 (1b) and Y11604 (4a)]. Phylogenetic trees were inferred using the neighbor-joining method <xref rid="pone.0087773-Saitou1" ref-type="bibr">[40]</xref>. Neighbor-joining was carried out using MEGA version 4.0.2 <xref rid="pone.0087773-Tamura1" ref-type="bibr">[41]</xref>. The resultant neighbor-joining tree and topology were evaluated by bootstrap analyses based on 1,000 re-samplings.</p></sec><sec id="s2f"><title>Prediction of novel CD4+ T cell epitopes and determination of mutations inside and outside CD4+ or CD8+ T cell epitopes</title><p>15-mer peptides containing an association between a particular HLA class II molecule and the sequenced NS5B with binding capacity &#x0003c;500 mM were screened <italic>in silico</italic> for the presence of the relevant HLA-binding motif <xref rid="pone.0087773-Mazumder1" ref-type="bibr">[42]</xref>. Mutations within the CD4+ and CD8+ T cell epitopes were defined as a sequence different from the consensus sequence within the four selected CD4+ T cell epitopes with above criteria and six known CD8+ T cell epitopes, respectively, on the basis of previous studies <xref rid="pone.0087773-Ruhl1" ref-type="bibr">[37]</xref>, <xref rid="pone.0087773-Chang1" ref-type="bibr">[43]</xref>&#x02013;<xref rid="pone.0087773-Kobayashi1" ref-type="bibr">[45]</xref>. Mutations outside the CD4+ or CD8+ T cell epitopes were counted according to the total number of mutations minus the sum of the respective epitope regions.</p></sec><sec id="s2g"><title>Statistical analyses</title><p>The results were expressed as percentages, means &#x000b1; SD, or as medians (range). The differences between the categorical variables were analyzed using Fisher's exact test or a Chi-square test. For continuous variables, the Student's t-test was used when the data showed a normal distribution, or the Mann-Whitney U test was used when the data was not normally distributed. The level of significance of each test was adjusted for multiple tests via Bonferroni correction. A p-value of &#x0003c;0.05 (two-tailed) was considered to be statistically significant. Statistical analysis of the data was performed using SPSS version 20 (IBM Corp. Armonk, NY, USA).</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Nested PCR-based distribution of GTs</title><p>Among 73 treatment-na&#x000ef;ve samples which were subject to cDNA synthesis, 23 (31.5%) were amplified. The quantification cycle (Cq) values of 50 samples not amplified (33.91&#x000b1;1.55) were significantly lower than those of the 23 amplified samples (32.76&#x000b1;1.17) (p&#x0200a;=&#x0200a;0.002). Similar to the serological prevalence, GT-1b (15 patients, 65.2%) and 2 (6 patients, 26.1%) were dominant in Koreans <xref rid="pone.0087773-Oh1" ref-type="bibr">[46]</xref>. GT-3a and 4 were amplified in one subject each (4.3%) (<xref ref-type="supplementary-material" rid="pone.0087773.s001">Table S1</xref>). Clinical details of the GT-1b patients for whom the sequences were amplified are presented in <xref ref-type="supplementary-material" rid="pone.0087773.s002">Table S2</xref>.</p></sec><sec id="s3b"><title>Phylogenetic analysis of GT-1b and its characteristics</title><p>A phylogenetic analysis based on the 492bp GT-1b sequenced NS5B region of randomly selected subclones showed distinct sequence variation between each subject (<xref ref-type="fig" rid="pone-0087773-g001">Fig. 1</xref>). All 15 subjects belonged to GT-1b. 12 subjects with N316/E464 and three subjects with C316/Q464 were phylogenetically segregated, showing high bootstrap values (75%). The C316/Q464 group had significantly lower Cq values [C316/Q464 (31.69&#x000b1;0.92) vs. N316/E464 (32.28&#x000b1;1.05), p&#x0200a;=&#x0200a;0.033] and exclusively showed advanced liver disease (CH + LC + HCC) (100%) compared to the other group (48.1%, p&#x0200a;=&#x0200a;0.001) at the subclonal level (<xref ref-type="table" rid="pone-0087773-t001">Table 1</xref>, <xref ref-type="supplementary-material" rid="pone.0087773.s003">Table S3</xref>). This finding indicates a positive correlation between viral replication and the clinical severity of liver disease. The nucleotide sequence of 166 subclones is available in the GenBank nucleotide sequence databases with the following accession numbers: KF422017-KF422027.</p><fig id="pone-0087773-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0087773.g001</object-id><label>Figure 1</label><caption><title>Phylogenic tree of 492bp of the GT-1b NS5B region.</title><p>Genetic distances were estimated using the Kimura two-parameter matrix and the phylogenetic tree was constructed using the neighbor-joining method. The percentages indicated at the nodes represent bootstrap levels supported by 1,000 re-sampled data sets. Bootstrap values of &#x0003c;70% are not shown.</p></caption><graphic xlink:href="pone.0087773.g001"/></fig><table-wrap id="pone-0087773-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0087773.t001</object-id><label>Table 1</label><caption><title>Mutation frequency at the major codons including antiviral resistance and SVR-related codons in the sequenced NS5B region.</title></caption><alternatives><graphic id="pone-0087773-t001-1" xlink:href="pone.0087773.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Amino acid variant types</td><td align="left" rowspan="1" colspan="1">No. of mutations (Total&#x0200a;=&#x0200a;166)</td><td align="left" rowspan="1" colspan="1">Rate (%)</td><td align="left" rowspan="1" colspan="1">No. of patient</td><td align="left" rowspan="1" colspan="1">Mutation type<xref ref-type="table-fn" rid="nt101">a</xref>
</td><td align="left" rowspan="1" colspan="1">Note (Reference)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Q309R</td><td align="left" rowspan="1" colspan="1">96</td><td align="left" rowspan="1" colspan="1">57.8</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">Diverse</td><td align="left" rowspan="1" colspan="1">SVR and ETR 27%, NR: 9% in Japan (15)</td></tr><tr><td align="left" rowspan="1" colspan="1">C316N<xref ref-type="table-fn" rid="nt102">b</xref>
</td><td align="left" rowspan="1" colspan="1">133</td><td align="left" rowspan="1" colspan="1">80.1</td><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1">Conserved</td><td align="left" rowspan="1" colspan="1">63.3% with C316N/Y in patients treated with IFN/RBV in Japan (15)</td></tr><tr><td align="left" rowspan="1" colspan="1">A333E/V</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">9.6</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">Conserved (E), Diverse (V)</td><td align="left" rowspan="1" colspan="1">SVR and ETR 23%, NR: 9% in Japan (15)</td></tr><tr><td align="left" rowspan="1" colspan="1">S335N</td><td align="left" rowspan="1" colspan="1">63</td><td align="left" rowspan="1" colspan="1">38.0</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">Diverse</td><td align="left" rowspan="1" colspan="1">29.6% with S335A/N in patients treated with IFN/RBV in Japan (15)</td></tr><tr><td align="left" rowspan="1" colspan="1">V338A</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">27.7</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">Diverse</td><td align="left" rowspan="1" colspan="1">SVR and ETR 18%, NR: 5% in Japan (15)</td></tr><tr><td align="left" rowspan="1" colspan="1">P353L</td><td align="left" rowspan="1" colspan="1">57</td><td align="left" rowspan="1" colspan="1">34.3</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">Diverse</td><td align="left" rowspan="1" colspan="1">17.3% with S335A/N in patients treated with IFN/RBV in Japan (15)</td></tr><tr><td align="left" rowspan="1" colspan="1">Q355K/R</td><td align="left" rowspan="1" colspan="1">34</td><td align="left" rowspan="1" colspan="1">20.5</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">Conserved</td><td align="left" rowspan="1" colspan="1">SVR and ETR 25%, NR: 5% in Japan (15)</td></tr><tr><td align="left" rowspan="1" colspan="1">E440D/G/K</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">24.1</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">Conserved (D), Diverse (G/K)</td><td align="left" rowspan="1" colspan="1">Immunosuppressant resistant mutation <xref rid="pone.0087773-Liu2" ref-type="bibr">[58]</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">C451H/T/Y</td><td align="left" rowspan="1" colspan="1">46</td><td align="left" rowspan="1" colspan="1">27.7</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">Conserved (T/Y), Diverse (H)</td><td align="left" rowspan="1" colspan="1">The frequency of 2 AA are almost same in Japan (16)</td></tr><tr><td align="left" rowspan="1" colspan="1">E464Q<xref ref-type="table-fn" rid="nt102">b</xref>
</td><td align="left" rowspan="1" colspan="1">33</td><td align="left" rowspan="1" colspan="1">19.9</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">Conserved</td><td align="left" rowspan="1" colspan="1">The frequency of 2 AA are almost same in Japan (16)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>a. &#x02018;Diverse&#x02019; indicates the mutation type of the coexistence with the wild type in a quasispecies distribution of a subject. Otherwise, &#x02018;Conserved&#x02019; indicates the presence of only mutation types alone without the wild type in a quasispecies distribution of a subject.</p></fn><fn id="nt102"><label/><p>b. C316/Q464 and N316/E464 were found in an exclusive manner. All the 33 subclones with the C316/Q464 type were found in patients with advanced liver disease, but not in Cs.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3c"><title>Distribution of mutations in the sequenced NS5B region</title><p>The distribution of the mutations from the sequenced GT-1b NS5B region aa 164 is shown in <xref ref-type="fig" rid="pone-0087773-g002">Fig. 2</xref>. There were six known CD8+ T cell epitopes (<xref ref-type="supplementary-material" rid="pone.0087773.s004">Table S4</xref>) <xref rid="pone.0087773-Ruhl1" ref-type="bibr">[37]</xref>, <xref rid="pone.0087773-Chang1" ref-type="bibr">[43]</xref>&#x02013;<xref rid="pone.0087773-Kobayashi1" ref-type="bibr">[45]</xref>, and the mutation frequencies inside the CD8+ T cell epitope regions (2.9%) were significantly higher than those outside the epitope regions (2.3%, p&#x0200a;=&#x0200a;0.001). The mutation frequencies inside the predicted CD4+ T cell epitopes (4.8%) were significantly higher than those outside the CD4+ T cell epitope (1.4%) and were even higher than those inside the known CD8+ T cell epitopes (p&#x0003c;0.001) (<xref ref-type="supplementary-material" rid="pone.0087773.s005">Table S5</xref>). We designated the region including the aa 333&#x02013;355 section of the CD4+ T cell epitopes as a mutational hotspot, as which an extraordinary high mutation frequency (6.7%) was observed (<xref ref-type="fig" rid="pone-0087773-g002">Fig. 2</xref>). Of note, the region was predicted to have high binding affinity for the various MHC class II HLA types prevalent in Koreans, raising the possibility that there may be distinctive MHC class II restricted immune pressure against HCV GT-1b in the mutational hotspot (<xref ref-type="table" rid="pone-0087773-t002">Table 2</xref>).</p><fig id="pone-0087773-g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0087773.g002</object-id><label>Figure 2</label><caption><title>Distribution and frequencies of the amino acid mutations in the NS5B AA 308&#x02013;471 regions.</title><p>The blue-shaded regions are the known MHC class I restricted regions and the red-lined regions are regions expected to be Korean-specific CD4+ epitope-binding regions. The region between the dotted lines is a mutational hotspot. The arrow indicates amino acid substitution related to IFN/RBV and other agents in HCV and the asterisks denote the novel mutations found in this study. The letters C and D indicate &#x02018;conserved&#x02019; and &#x02018;diverse&#x02019; in the subclones, respectively.</p></caption><graphic xlink:href="pone.0087773.g002"/></fig><table-wrap id="pone-0087773-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0087773.t002</object-id><label>Table 2</label><caption><title>Comparison of mutation rates between the CD4+ and CD8+ T cell epitope regions.</title></caption><alternatives><graphic id="pone-0087773-t002-2" xlink:href="pone.0087773.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Regions (n&#x0200a;=&#x0200a;27,224)</td><td align="left" rowspan="1" colspan="1">No. of mutations/No. of codons</td><td align="left" rowspan="1" colspan="1">Mutation rate (%)</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic>-value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Outside known CD8+</td><td align="left" rowspan="1" colspan="1">425/18,758</td><td align="left" rowspan="1" colspan="1">2.3</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Inside known CD8+</td><td align="left" rowspan="1" colspan="1">249/8,466</td><td align="left" rowspan="1" colspan="1">2.9</td><td align="left" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="nt103">a</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Outside predicted CD4+</td><td align="left" rowspan="1" colspan="1">250/18,426</td><td align="left" rowspan="1" colspan="1">1.4</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">Predicted CD4+</td><td align="left" rowspan="1" colspan="1">424/8,798</td><td align="left" rowspan="1" colspan="1">4.8</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="nt104">b</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Mutational hotspot_1</td><td align="left" rowspan="1" colspan="1">254/3,818</td><td align="left" rowspan="1" colspan="1">6.7</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="nt104">b</xref>
</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt103"><label/><p>a. P-values were determined by a comparison of mutation rates of inside and outside of the CD8+ T cell epitopes.</p></fn><fn id="nt104"><label/><p>b. P-values (&#x0003c;0.001) were obtained by a comparison of the mutation rates of outside of the CD4+ T cell epitopes as well as inside the CD8+ T cell epitopes.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3d"><title>Comparison of synonymous (d<sub>S</sub>) and nonsynonymous mutations (d<sub>N</sub>) according to the NS5B region</title><p>The distinctive CD4+ T cell-mediated immune pressure was examined by comparing d<sub>N</sub> to d<sub>S</sub>. The d<sub>N</sub>/d<sub>S</sub> ratio inside the known CD8+ T cell epitopes (0.29) was slightly higher than that of the outside (0.21) region with d<sub>N</sub> frequencies of 2.9% and 2.3%, respectively. The d<sub>N</sub>/d<sub>S</sub> ratio inside the predicted CD4+ T cell epitopes (0.49) was statistically higher than that outside (0.13), with d<sub>N</sub> frequencies of 4.8% and 1.4%, respectively, although the d<sub>S</sub> frequency outside the predicted CD4+ T cell epitopes was higher at a statistically significant level. The odds ratio of the d<sub>N</sub> inside and outside the predicted CD4+ T cell epitopes was 3.55. In the mutational hotspot, d<sub>N</sub> frequencies (11.1%) were found to be higher than d<sub>S</sub> frequencies (4.8%), resulting in an elevated d<sub>N</sub>/d<sub>S</sub> ratio (1.4). This suggests there are strong MHC class II restricted immune pressures against HCV NS5B in chronic Korean patients (<xref ref-type="table" rid="pone-0087773-t003">Table 3</xref>).</p><table-wrap id="pone-0087773-t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0087773.t003</object-id><label>Table 3</label><caption><title>Frequencies of d<sub>N</sub> and d<sub>S</sub> according to the NS5B region.</title></caption><alternatives><graphic id="pone-0087773-t003-3" xlink:href="pone.0087773.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Regions</td><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">Inside</td><td align="left" rowspan="1" colspan="1">Outside</td><td align="left" rowspan="1" colspan="1">Odds ratio</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Known CD8+</td><td align="left" rowspan="1" colspan="1">No. of Codons</td><td align="left" rowspan="1" colspan="1">8,466</td><td align="left" rowspan="1" colspan="1">18,758</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">(51 AA)</td><td align="left" rowspan="1" colspan="1">d<sub>N</sub> (%)</td><td align="left" rowspan="1" colspan="1">249 (2.9)</td><td align="left" rowspan="1" colspan="1">426 (2.3)</td><td align="left" rowspan="1" colspan="1">1.30<xref ref-type="table-fn" rid="nt105">a</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">d<sub>S</sub> (%)</td><td align="left" rowspan="1" colspan="1">868 (10.3)</td><td align="left" rowspan="1" colspan="1">1,992 (10.6)</td><td align="left" rowspan="1" colspan="1">0.97</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">d<sub>N</sub>/d<sub>S</sub> ratio</td><td align="left" rowspan="1" colspan="1">0.29</td><td align="left" rowspan="1" colspan="1">0.21</td><td align="left" rowspan="1" colspan="1">1.34</td></tr><tr><td align="left" rowspan="1" colspan="1">Known CD4+</td><td align="left" rowspan="1" colspan="1">No. of Codons</td><td align="left" rowspan="1" colspan="1">8,798</td><td align="left" rowspan="1" colspan="1">18,426</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">(53 AA)</td><td align="left" rowspan="1" colspan="1">d<sub>N</sub> (%)</td><td align="left" rowspan="1" colspan="1">424 (4.8)</td><td align="left" rowspan="1" colspan="1">250 (1.4)</td><td align="left" rowspan="1" colspan="1">3.55<xref ref-type="table-fn" rid="nt106">b</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">d<sub>S</sub> (%)</td><td align="left" rowspan="1" colspan="1">863 (9.8)</td><td align="left" rowspan="1" colspan="1">1,997 (10.8)</td><td align="left" rowspan="1" colspan="1">0.91<xref ref-type="table-fn" rid="nt107">c</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">d<sub>N</sub>/d<sub>S</sub> ratio</td><td align="left" rowspan="1" colspan="1">0.49</td><td align="left" rowspan="1" colspan="1">0.13</td><td align="left" rowspan="1" colspan="1">3.92</td></tr><tr><td align="left" rowspan="1" colspan="1">Mutational hotspot</td><td align="left" rowspan="1" colspan="1">No. of Codons</td><td align="left" rowspan="1" colspan="1">3,818</td><td align="left" rowspan="1" colspan="1">23,406</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">(23 AA)</td><td align="left" rowspan="1" colspan="1">d<sub>N</sub> (%)</td><td align="left" rowspan="1" colspan="1">254 (6.7)</td><td align="left" rowspan="1" colspan="1">420 (1.8)</td><td align="left" rowspan="1" colspan="1">3.71<xref ref-type="table-fn" rid="nt106">b</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">d<sub>S</sub> (%)</td><td align="left" rowspan="1" colspan="1">182 (4.8)</td><td align="left" rowspan="1" colspan="1">2,678 (11.4)</td><td align="left" rowspan="1" colspan="1">0.42<xref ref-type="table-fn" rid="nt106">b</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">d<sub>N</sub>/d<sub>S</sub> ratio</td><td align="left" rowspan="1" colspan="1">1.4</td><td align="left" rowspan="1" colspan="1">0.16</td><td align="left" rowspan="1" colspan="1">8.90</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt105"><label/><p>a. p&#x0200a;=&#x0200a;0.001;</p></fn><fn id="nt106"><label/><p>b. p&#x0003c;0.001;</p></fn><fn id="nt107"><label/><p>c. p&#x0200a;=&#x0200a;0.01.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3e"><title>Comparisons of d<sub>S</sub> and d<sub>N</sub> in the NS5B region between Korean patients and patients from other countries</title><p>To examine whether there was distinctive immune pressure against HCV NS5B at the CD4+ T cell level in Koreans, we compared d<sub>S</sub> and d<sub>N</sub> in the NS5B region between 15 Korean patients and 60 patients from other countries (China: 15, Japan: 15, Switzerland: 15 and the United States: 15). In the Koreans subjects, we used the consensus sequences of NS5B from more than 10 subclones of patients. For the patients from other countries, we used sequences retrieved from the LANL HCV database. In the NS5B region, the d<sub>N</sub>/d<sub>S</sub> ratio for the Korean subjects (0.23) was higher than it was for those from other countries (1.4) with statistical support (p&#x0200a;=&#x0200a;0.002). The d<sub>N</sub> frequency (3.1) in the known CD8+ T cell epitopes from Korean patients was higher than that for the patients from other countries (2.1), but the difference was not statistically significant (p&#x0200a;=&#x0200a;0.078). However, the d<sub>N</sub> frequency (4.5%) in the predicted CD4+ T cell epitope regions in the Korean patients was significantly higher than that in those from other countries (2.2%) (p&#x0003c;0.001). The d<sub>N</sub>/d<sub>S</sub> ratios in the predicted CD4+ T cell epitope regions were higher in the Koreans (0.52) by nearly twofold compared to those of the patients from other areas (0.26). In particularly, the difference in the d<sub>N</sub> frequency between the Koreans (6.4%) and the patients from other countries (2.3%) was more pronounced in the mutational hotspot. Collectively, these results suggest the presence of distinctive CD4+ T cell mediated immune pressure against HCV NS5B in Koreans (<xref ref-type="table" rid="pone-0087773-t004">Table 4</xref>).</p><table-wrap id="pone-0087773-t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0087773.t004</object-id><label>Table 4</label><caption><title>Comparison of the frequencies of d<sub>N</sub> and d<sub>S</sub> of the NS5B regions between 15 Korean patients consensus sequence and patients from other countries.</title></caption><alternatives><graphic id="pone-0087773-t004-4" xlink:href="pone.0087773.t004"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Regions</td><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">Korean (n&#x0200a;=&#x0200a;15)</td><td align="left" rowspan="1" colspan="1">Other countries<xref ref-type="table-fn" rid="nt108">a</xref> (n&#x0200a;=&#x0200a;60)</td><td align="left" rowspan="1" colspan="1">Odds ratio</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">No. of Codons</td><td align="left" rowspan="1" colspan="1">2,460</td><td align="left" rowspan="1" colspan="1">9,840</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">(164 AA)</td><td align="left" rowspan="1" colspan="1">d<sub>N</sub> (%)</td><td align="left" rowspan="1" colspan="1">57 (2.3)</td><td align="left" rowspan="1" colspan="1">142 (1.4)</td><td align="left" rowspan="1" colspan="1">1.61<xref ref-type="table-fn" rid="nt109">b</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">d<sub>S</sub> (%)</td><td align="left" rowspan="1" colspan="1">252 (10.2)</td><td align="left" rowspan="1" colspan="1">914 (9.3)</td><td align="left" rowspan="1" colspan="1">1.10</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">d<sub>N</sub>/dS ratio</td><td align="left" rowspan="1" colspan="1">0.23</td><td align="left" rowspan="1" colspan="1">0.16</td><td align="left" rowspan="1" colspan="1">1.46</td></tr><tr><td align="left" rowspan="1" colspan="1">Known CD8+</td><td align="left" rowspan="1" colspan="1">No. of Codons</td><td align="left" rowspan="1" colspan="1">765</td><td align="left" rowspan="1" colspan="1">3,060</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">(51 AA)</td><td align="left" rowspan="1" colspan="1">d<sub>N</sub> (%)</td><td align="left" rowspan="1" colspan="1">24 (3.1)</td><td align="left" rowspan="1" colspan="1">63 (2.1)</td><td align="left" rowspan="1" colspan="1">1.52<xref ref-type="table-fn" rid="nt110">c</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">dS (%)</td><td align="left" rowspan="1" colspan="1">65 (8.5)</td><td align="left" rowspan="1" colspan="1">290 (9.5)</td><td align="left" rowspan="1" colspan="1">0.90</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">d<sub>N</sub>/dS ratio</td><td align="left" rowspan="1" colspan="1">0.37</td><td align="left" rowspan="1" colspan="1">0.22</td><td align="left" rowspan="1" colspan="1">1.70</td></tr><tr><td align="left" rowspan="1" colspan="1">Predicted CD4+</td><td align="left" rowspan="1" colspan="1">No. of Codons</td><td align="left" rowspan="1" colspan="1">795</td><td align="left" rowspan="1" colspan="1">3,180</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">(53 AA)</td><td align="left" rowspan="1" colspan="1">d<sub>N</sub> (%)</td><td align="left" rowspan="1" colspan="1">36 (4.5)</td><td align="left" rowspan="1" colspan="1">69 (2.2)</td><td align="left" rowspan="1" colspan="1">2.12<xref ref-type="table-fn" rid="nt111">d</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">d<sub>S</sub> (%)</td><td align="left" rowspan="1" colspan="1">69 (8.7)</td><td align="left" rowspan="1" colspan="1">261 (8.2)</td><td align="left" rowspan="1" colspan="1">1.06</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">d<sub>N</sub>/d<sub>S</sub> ratio</td><td align="left" rowspan="1" colspan="1">0.52</td><td align="left" rowspan="1" colspan="1">0.26</td><td align="left" rowspan="1" colspan="1">1.97</td></tr><tr><td align="left" rowspan="1" colspan="1">Mutational hotspot</td><td align="left" rowspan="1" colspan="1">No. of Codons</td><td align="left" rowspan="1" colspan="1">345</td><td align="left" rowspan="1" colspan="1">1,380</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">(23 AA)</td><td align="left" rowspan="1" colspan="1">d<sub>N</sub> (%)</td><td align="left" rowspan="1" colspan="1">22 (6.4)</td><td align="left" rowspan="1" colspan="1">32 (2.3)</td><td align="left" rowspan="1" colspan="1">2.75<xref ref-type="table-fn" rid="nt111">d</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">d<sub>S</sub> (%)</td><td align="left" rowspan="1" colspan="1">16 (4.6)</td><td align="left" rowspan="1" colspan="1">53 (3.8)</td><td align="left" rowspan="1" colspan="1">1.21</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">d<sub>N</sub>/d<sub>S</sub> ratio</td><td align="left" rowspan="1" colspan="1">1.38</td><td align="left" rowspan="1" colspan="1">0.60</td><td align="left" rowspan="1" colspan="1">2.28</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt108"><label/><p>a. China: 15, Japan: 15, Switzerland: 15 and the United States: 15.</p></fn><fn id="nt109"><label/><p>b. p&#x0200a;=&#x0200a;0.002;</p></fn><fn id="nt110"><label/><p>c: p&#x0200a;=&#x0200a;0.078;</p></fn><fn id="nt111"><label/><p>d: p&#x0003c;0.001.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3f"><title>Correlation between NS5B mutations and the severity of liver disease</title><p>The overall mutation frequency of the entire NS5B region in C (2.8%) was significantly higher than in the comparison group, patients with CH, those with liver cirrhosis LC and those with HCC (2.2%) (p&#x0200a;=&#x0200a;0.002). The mutation frequency in known CD8+ T cell epitopes was also significantly higher in C than in the comparison group [C (3.4%) vs. CH + LC + HCC (2.6%), p&#x0200a;=&#x0200a;0.05]. This tendency was also found in the predicted CD4+ T cell epitopes [C (5.7%) vs. CH + LC + HCC (4.2%), p&#x0200a;=&#x0200a;0.001] and in the mutational hotspot [C (7.7%) vs. CH + LC + HCC (5.9%), p&#x0200a;=&#x0200a;0.004] with an increased frequency of mutations at a statistically significant level. This shows that increases in the mutation rate in the NS5B region are negatively correlated with the progression of liver disease in chronic hepatitis C patients (<xref ref-type="table" rid="pone-0087773-t005">Table 5</xref>).</p><table-wrap id="pone-0087773-t005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0087773.t005</object-id><label>Table 5</label><caption><title>Comparison of the mutation rates in NS5B regions according to the clinical status of liver disease.</title></caption><alternatives><graphic id="pone-0087773-t005-5" xlink:href="pone.0087773.t005"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Regions (n&#x0200a;=&#x0200a;27,224)</td><td align="left" rowspan="1" colspan="1">C (%)/No. of codons</td><td align="left" rowspan="1" colspan="1">CH+LC+HCC (%)/No. of codons</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic>-value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">320 (2.8)/11,316</td><td align="left" rowspan="1" colspan="1">354 (2.2)/15,908</td><td align="left" rowspan="1" colspan="1">0.002<xref ref-type="table-fn" rid="nt112">a</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Known CD8+</td><td align="left" rowspan="1" colspan="1">119 (3.4)/3,519</td><td align="left" rowspan="1" colspan="1">130 (2.6)/4,947</td><td align="left" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Predicted CD4+</td><td align="left" rowspan="1" colspan="1">208 (5.7)/3,657</td><td align="left" rowspan="1" colspan="1">216 (4.2)/5,141</td><td align="left" rowspan="1" colspan="1">0.001<xref ref-type="table-fn" rid="nt112">a</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Mutational hotspot</td><td align="left" rowspan="1" colspan="1">122 (7.7)/1,587</td><td align="left" rowspan="1" colspan="1">132 (5.9)/2,231</td><td align="left" rowspan="1" colspan="1">0.004<xref ref-type="table-fn" rid="nt112">a</xref>
</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt112"><label/><p>a. Statistically significant after a Bonferroni post hoc analysis (p&#x0003c;0.05).</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3g"><title>Mutation frequency in codons related to SVR and ETR in Korean patients</title><p>Mutations at the 309, 333, 338 and 355 codons are reportedly related to SVR and ETR groups as compared to non-responders (NR) <xref rid="pone.0087773-Hamano1" ref-type="bibr">[15]</xref>. Interestingly, a very high mutation rate in four SVR-related codons was found in Korean treatment-na&#x000ef;ve patients, with an average mutation frequency of 28.9% (192/664) in the quasispecies distributions. Of note, the average mutation frequency (31.7%) in four codons as calculated from 15 Korean patients was significantly higher than any of the other regions, including that from Japan (<xref ref-type="table" rid="pone-0087773-t006">Table 6</xref>).</p><table-wrap id="pone-0087773-t006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0087773.t006</object-id><label>Table 6</label><caption><title>Comparison of mutation rates in four SVR-related codons (309, 333, 338 and 355) in the NS5B region between 15 Korean consensus sequence and patients from other countries.</title></caption><alternatives><graphic id="pone-0087773-t006-6" xlink:href="pone.0087773.t006"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Countries (n&#x0200a;=&#x0200a;15)</td><td align="left" rowspan="1" colspan="1">No. of mutations (n&#x0200a;=&#x0200a;60)</td><td align="left" rowspan="1" colspan="1">Mutation rate (%)</td><td align="left" rowspan="1" colspan="1">
<italic>P</italic>-value<xref ref-type="table-fn" rid="nt113">a</xref>
</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Korea</td><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">31.7</td><td align="left" rowspan="1" colspan="1">-</td></tr><tr><td align="left" rowspan="1" colspan="1">China</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="nt114">b</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Japan</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">11.7</td><td align="left" rowspan="1" colspan="1">0.014</td></tr><tr><td align="left" rowspan="1" colspan="1">Switzerland</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="nt114">b</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">United States</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1.7</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001<xref ref-type="table-fn" rid="nt114">b</xref>
</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt113"><label/><p>a. P-values were determined by a comparison with the mutation rate from 15 Korean consensus sequences.</p></fn><fn id="nt114"><label/><p>b. Statistically significant after a Bonferroni post hoc analysis (p&#x0003c;0.05).</p></fn></table-wrap-foot></table-wrap><p>A quasispecies analysis showed a total of 10 mutations, including SVR and antiviral resistance in the sequenced NS5B region. These can be divided into two distinct groups. One is the diverse (D) type, which coexists with other quasispecies members in a patient, and the other is made up of conserved (C) types which exist alone without a quasispecies counterpart in a patient (<xref ref-type="fig" rid="pone-0087773-g002">Fig. 2</xref>, <xref ref-type="table" rid="pone-0087773-t001">Table 1</xref>). The coexistence of diverse quasispecies at a specific codon may be indirect evidence of an important target for immune pressure or/and viral fitness. Notably, the coexistence of Q and R at codon 309, located in one of the CD8+ T cell epitopes (aa 308 and 315), was found in all 15 Korean subjects via a quasispecies distribution analysis; this may be due to the distinct CD8+ T cell immune pressure against a region between aa 308 and 315 among Koreans (<xref ref-type="supplementary-material" rid="pone.0087773.s006">Table S6</xref>). In addition, there were other D type mutations: A333V, S335N, V338A, P353L, E440G/K and C451H. On the other hand, there were only three C types of mutations (C316N, Q355K/R and E464Q). Interestingly, in all the three C-type mutations, significantly different Cq values between two counterparts in the respective mutation type were found (<xref ref-type="supplementary-material" rid="pone.0087773.s003">Table S3</xref>).</p></sec></sec><sec id="s4"><title>Discussion</title><p>The presence of distinct HLA types among an ethnic group could lead to distinct MHC class I or II restricted immune pressures within its population <xref rid="pone.0087773-Ruhl1" ref-type="bibr">[37]</xref>, <xref rid="pone.0087773-Chang1" ref-type="bibr">[43]</xref>, <xref rid="pone.0087773-NeumannHaefelin1" ref-type="bibr">[44]</xref>, <xref rid="pone.0087773-NeumannHaefelin2" ref-type="bibr">[47]</xref>. Therefore, the frequency and patterns of escape variants against structural and nonstructural HCV proteins reflect the background HLA types among an ethnic group <xref rid="pone.0087773-Jaspe1" ref-type="bibr">[48]</xref>, <xref rid="pone.0087773-Thio1" ref-type="bibr">[49]</xref>. The aim of the present study is to investigate the background mutation frequency and patterns of HCV NS5B, reportedly related to a high SVR, from treatment-na&#x000ef;ve Korean patients chronically infected with GT-1b in an effort to explain the high SVR in Korean patients. The significant findings of this study are discussed below.</p><p>First, the entire mutation frequency in the sequenced NS5B region was positively correlated with Cs but not with patients showing disease progression (CH, LC and HCC) [C (2.8%) vs. CH + LC + HCC (2.2%), p&#x0200a;=&#x0200a;0.002]. Furthermore, similar mutation frequencies were noted within both the CD4+ (p&#x0200a;=&#x0200a;0.001) and CD8+ T cell epitope regions (p&#x0200a;=&#x0200a;0.05) (<xref ref-type="table" rid="pone-0087773-t005">Table 5</xref>). This suggests that the accumulation of multiple mutations in NS5B may be induced by vigorous and multi-specific immune pressure in the HCV-acute infection phase and may lead to the functional abnormality of HCV RdRp activity, resulting in the attenuation of HCV pathogenic potentials <xref rid="pone.0087773-Blackard1" ref-type="bibr">[19]</xref>. This strongly supports previous results which showed that mutations in NS5B were related to the high SVR and EVR of GT-1b chronically infected patients <xref rid="pone.0087773-Hamano1" ref-type="bibr">[15]</xref>.</p><p>Second, a pronounced d<sub>N</sub> frequency in the predicted CD4+ T cell epitopes in the NS5B region [Korean (4.5%) vs. those of patients from other countries (2.1%), p&#x0200a;=&#x0200a;0.001], particularly in the mutational hotspot [Korean (6.4%) vs. other countries (3.1%), p&#x0200a;=&#x0200a;0.01], was found in Korean patients but not in patients from other areas (<xref ref-type="table" rid="pone-0087773-t004">Table 4</xref>). This suggests that there is distinct intrahepatic MHC class II restricted immune pressure at least against HCV NS5B among the Korean population <xref rid="pone.0087773-Blackard1" ref-type="bibr">[19]</xref>. Broadly directed virus-specific immune pressure at the CD4+ T cell level was recently reported to play a very pivotal role in spontaneous resolution at a very early phase of HCV-acute infection <xref rid="pone.0087773-SchulzeZurWiesch1" ref-type="bibr">[50]</xref>. Furthermore, the presence of the multi-specific CD4+ T cell response against HCV can aid not only the induction of a vigorous antiviral CD8+ T cell response but also antibody production for the inhibition of the spread of the virus <xref rid="pone.0087773-Grakoui1" ref-type="bibr">[51]</xref>. Particularly, because three codons (A333, V338 and Q355) out of four reported to be related to the high SVR are located in the mutational hotspot, the acquisition of mutations within this region induced by the distinctive Korean immune pressure at the CD4+ T cell level may contribute to the high SVR found in Korean patients infected with GT-1b. In fact, the prediction of the MHC class II HLA allele showed that a region of the CD4+ T cell epitope from NS5B, covering aa 333 to 347, one of two predicted epitopes comprising the mutational hotspot, has high binding affinity for most HLA DRB1 alleles prevalent in Korean populations <xref rid="pone.0087773-Chung1" ref-type="bibr">[52]</xref>. In addition, HLA DQB1 03:01 and 03:02, prevalent at frequencies higher than 10% in Koreans, also are noted to be associated with viral clearance <xref rid="pone.0087773-Minton1" ref-type="bibr">[53]</xref>&#x02013;<xref rid="pone.0087773-Ali1" ref-type="bibr">[55]</xref>. Our previous study also showed that there are distinct mutation patterns and a very high mutation frequency of the CD4+ T cell epitopes of the HBV preC/Core region in chronic Korean patients, strongly supporting the hypothesis of this study <xref rid="pone.0087773-Kim1" ref-type="bibr">[56]</xref>.</p><p>Third, the frequency of d<sub>N</sub> within the CD8+ T cell epitope region of NS5B was significantly higher than that outside the CD8+ T cell epitope region [inside CD8+ (2.9%) vs. outside (2.3%), p&#x0200a;=&#x0200a;0.001], suggesting the presence of immune pressure at the CD8+ T cell level against HCV NS5B among Korean patients, as shown in patients from other areas (<xref ref-type="table" rid="pone-0087773-t003">Table 3</xref>) <xref rid="pone.0087773-Ruhl1" ref-type="bibr">[37]</xref>, <xref rid="pone.0087773-NeumannHaefelin1" ref-type="bibr">[44]</xref>, <xref rid="pone.0087773-NeumannHaefelin2" ref-type="bibr">[47]</xref>, <xref rid="pone.0087773-NeumannHaefelin3" ref-type="bibr">[57]</xref>. However, pronounced differences in the mutation frequency between six regions of CD8+ T cell epitopes were found. Two of the six CD8+ T cell epitopes (308 to 315 aa and 451 to 459) with high binding affinity to two HLA allele types, HLA-A02:01 and HLA-A24:02, prevalent in Koreans, showed a higher d<sub>N</sub> frequency compared to other epitopes [308&#x02013;315: 96 (7.2%) and 451&#x02013;459: 49 (3.3%)], suggesting the presence of distinct MHC class I restricted immune pressure in Korean patients <xref rid="pone.0087773-Chung1" ref-type="bibr">[52]</xref>. Particularly, it is noteworthy that the extraordinary high d<sub>N</sub>/d<sub>S</sub> ratio (2.04) found in a region of the CD8+ T cell epitope covering codons 308 to 315, was mainly due to the presence of frequent mutations in codon 309, one of four codons related to SVR rates (<xref ref-type="supplementary-material" rid="pone.0087773.s004">Table S4</xref>, <xref ref-type="fig" rid="pone-0087773-g002">Fig. 2</xref>). The mutation type, Q309R, is known to be frequently mutated in NS5B, particularly in Asian patients. However, even compared to Japanese patients, also an Asian country like Korea, the strikingly high mutation frequency of Q309R was observed in only the Korean patients <xref rid="pone.0087773-Hamano1" ref-type="bibr">[15]</xref>, <xref rid="pone.0087773-Watanabe1" ref-type="bibr">[16]</xref>. All of the 15 patients harbored this mutation in their quasispecies distribution and more than half (96/166, 57.8%) of all quasispecies from the 15 patients had the mutation type R309. Interestingly, the co-existence of both mutated and wild types, not exclusive of the existence of one type alone, was found in all 15 patients, suggesting the advantage of the coexistence of two variants in a patient over the exclusive existence of either type alone in an escape of host immune surveillance or viral fitness (<xref ref-type="supplementary-material" rid="pone.0087773.s006">Table S6</xref>). Therefore, the high frequency of the Q309R mutation in Korean patients may be induced by CD8+ T cell immune pressure which may in part provide a likely explanation for the high SVR rates in Koreans.</p><p>Finally, it is well known that mutations in NS5B can affect the HCV replication capacity <xref rid="pone.0087773-Blackard1" ref-type="bibr">[19]</xref>. We found a total of three types of mutations (C316N, Q355K/R and E464Q) which had a significant effect on HCV replication (Cq value: C316N and E464Q p&#x0200a;=&#x0200a;0.033, Q355K/R p&#x0200a;=&#x0200a;0.003) (<xref ref-type="supplementary-material" rid="pone.0087773.s003">Table S3</xref>). Interestingly, our quasispecies analysis showed that two polymorphisms in aa 316, C316 and N316, were strongly related to two polymorphisms in codon 464, Q464 and E464, respectively, in an exclusive manner (<xref ref-type="fig" rid="pone-0087773-g001">Figure 1</xref>). The type with both C316 and Q464 signatures showed a significantly higher HCV replication capacity and was more related to patients with advanced liver disease compared to the type with both the N316 and E464 signatures. The exclusive combination of the SNPs of two codons may be due to the structural constraint of NS5B. Furthermore, the coexistence of both types (C316/Q464 and N316/E464) was not found in any patients, suggesting that these two types may be from completely different resources and not a different quasispecies version induced by immune pressure from a patient. Our data showing phylogenetic segregation between the two types also supports the above hypothesis.</p><p>Our study has three potential limitations. First, the nested PCR protocol used in this study showed low sensitivity, with the amplification of only 23 samples out of 73 samples (31.5%). The strategies for the nested PCR protocol including primer sets and a PCR condition should be modified in the future study. Particularly, PCR negative amplifications were found with high frequencies in samples with lower HCV viral loads, suggesting novel nested PCR protocol to increase the degree of sensitivity should be applied in a future study. Second, the modest population size (15 patients) is relatively small to lead to a meaningful conclusion about the relationship between NS5B mutations and liver disease progression. Third, as single-genome amplification and an end-point dilution strategy were not utilized, the cloning strategy employed in this study is limited when used to represent genuine viral quasispecies in serum samples.</p><p>In conclusion, our data suggest that the distinct MHC class II restricted immune pressure against HCV NS5B in Korean patients leads to a pronounced high mutation frequency and distinct mutation patterns in HCV NS5B in Korean patients. This finding provides important insight into the high SVR and ETR rates during the treatment of GT-1b infected Korean patients.</p></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0087773.s001"><label>Table S1</label><caption><p>Distribution of amplified subjects by PCR targeting NS5B sequences.</p><p>(DOCX)</p></caption><media xlink:href="pone.0087773.s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0087773.s002"><label>Table S2</label><caption><p>Clinical features of 15 Korean patients in this study.</p><p>(DOCX)</p></caption><media xlink:href="pone.0087773.s002.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0087773.s003"><label>Table S3</label><caption><p>Comparison of Cq values between types at the major codons including antiviral resistance and SVR related in the sequenced NS5B region.</p><p>(DOCX)</p></caption><media xlink:href="pone.0087773.s003.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0087773.s004"><label>Table S4</label><caption><p>Comparison of amino acid sequences, dominant HLA allele, d<sub>N</sub>/d<sub>S</sub> ratio between six regions of Known CD8+ T cell epitopes in the NS5B region.</p><p>(DOCX)</p></caption><media xlink:href="pone.0087773.s004.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0087773.s005"><label>Table S5</label><caption><p>Relationships of predicted CD4+ T cell epitopes of the NS5B with MHC class II HLA types prevalent in Korean population.</p><p>(DOCX)</p></caption><media xlink:href="pone.0087773.s005.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0087773.s006"><label>Table S6</label><caption><p>Quasispecies distribution at the codon 309 in 15 Korean patients.</p><p>(DOCX)</p></caption><media xlink:href="pone.0087773.s006.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pone.0087773-Chen1"><label>1</label><mixed-citation publication-type="journal">
<name><surname>Chen</surname><given-names>SL</given-names></name>, <name><surname>Morgan</surname><given-names>TR</given-names></name> (<year>2006</year>) <article-title>The natural history of hepatitis C virus (HCV) infection</article-title>. <source>Int J Med Sci</source>
<volume>3</volume>: <fpage>47</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">16614742</pub-id></mixed-citation></ref><ref id="pone.0087773-Soriano1"><label>2</label><mixed-citation publication-type="journal">
<name><surname>Soriano</surname><given-names>V</given-names></name>, <name><surname>Peters</surname><given-names>MG</given-names></name>, <name><surname>Zeuzem</surname><given-names>S</given-names></name> (<year>2009</year>) <article-title>New therapies for hepatitis C virus infection</article-title>. <source>Clin Infect Dis</source>
<volume>48</volume>: <fpage>313</fpage>&#x02013;<lpage>320</lpage>.<pub-id pub-id-type="pmid">19123867</pub-id></mixed-citation></ref><ref id="pone.0087773-Tanaka1"><label>3</label><mixed-citation publication-type="journal">
<name><surname>Tanaka</surname><given-names>Y</given-names></name>, <name><surname>Nishida</surname><given-names>N</given-names></name>, <name><surname>Sugiyama</surname><given-names>M</given-names></name>, <name><surname>Kurosaki</surname><given-names>M</given-names></name>, <name><surname>Matsuura</surname><given-names>K</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet</article-title>. <volume>41</volume>: <fpage>1105</fpage>&#x02013;<lpage>1109</lpage>.</mixed-citation></ref><ref id="pone.0087773-Brown1"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Brown</surname><given-names>RS</given-names><suffix>Jr</suffix></name>, <name><surname>Gaglio</surname><given-names>PJ</given-names></name> (<year>2003</year>) <article-title>Scope of worldwide hepatitis C problem</article-title>. <source>Liver Transpl</source>
<volume>9</volume>: <fpage>S10</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="pmid">14586889</pub-id></mixed-citation></ref><ref id="pone.0087773-Seeff1"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Seeff</surname><given-names>LB</given-names></name> (<year>2002</year>) <article-title>Natural history of chronic hepatitis C. Hepatology</article-title>. <volume>36</volume>: <fpage>S35</fpage>&#x02013;<lpage>S46</lpage>.</mixed-citation></ref><ref id="pone.0087773-Gerlach1"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Gerlach</surname><given-names>JT</given-names></name>, <name><surname>Diepolder</surname><given-names>HM</given-names></name>, <name><surname>Zachoval</surname><given-names>R</given-names></name>, <name><surname>Gruener</surname><given-names>NH</given-names></name>, <name><surname>Jung</surname><given-names>MC</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>Acute hepatitis C: High rate of both spontaneous and treatment-induced viral clearance</article-title>. <source>Gastroenterology</source>
<volume>125</volume>: <fpage>80</fpage>&#x02013;<lpage>88</lpage>.<pub-id pub-id-type="pmid">12851873</pub-id></mixed-citation></ref><ref id="pone.0087773-Liu1"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Liu</surname><given-names>L</given-names></name>, <name><surname>Fisher</surname><given-names>BE</given-names></name>, <name><surname>Dowd</surname><given-names>KA</given-names></name>, <name><surname>Astemborski</surname><given-names>J</given-names></name>, <name><surname>Cox</surname><given-names>AL</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection</article-title>. <source>J Virol</source>
<volume>84</volume>: <fpage>5067</fpage>&#x02013;<lpage>5077</lpage>.<pub-id pub-id-type="pmid">20200239</pub-id></mixed-citation></ref><ref id="pone.0087773-Akuta1"><label>8</label><mixed-citation publication-type="journal">
<name><surname>Akuta</surname><given-names>N</given-names></name>, <name><surname>Suzuki</surname><given-names>F</given-names></name>, <name><surname>Sezaki</surname><given-names>H</given-names></name>, <name><surname>Suzuki</surname><given-names>Y</given-names></name>, <name><surname>Hosaka</surname><given-names>T</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy</article-title>. <source>Intervirology</source>
<volume>48</volume>: <fpage>372</fpage>&#x02013;<lpage>380</lpage>.<pub-id pub-id-type="pmid">16024941</pub-id></mixed-citation></ref><ref id="pone.0087773-Conjeevaram1"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Conjeevaram</surname><given-names>HS</given-names></name>, <name><surname>Fried</surname><given-names>MW</given-names></name>, <name><surname>Jeffers</surname><given-names>LJ</given-names></name>, <name><surname>Terrault</surname><given-names>NA</given-names></name>, <name><surname>Wiley-Lucas</surname><given-names>TE</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1</article-title>. <source>Gastroenterology</source>
<volume>131</volume>: <fpage>470</fpage>&#x02013;<lpage>477</lpage>.<pub-id pub-id-type="pmid">16890601</pub-id></mixed-citation></ref><ref id="pone.0087773-Missiha1"><label>10</label><mixed-citation publication-type="journal">
<name><surname>Missiha</surname><given-names>S</given-names></name>, <name><surname>Heathcote</surname><given-names>J</given-names></name>, <name><surname>Arenovich</surname><given-names>T</given-names></name>, <name><surname>Khan</surname><given-names>K</given-names></name>, <name><surname>Canadian Pegasys Expanded Access</surname><given-names>G</given-names></name> (<year>2007</year>) <article-title>Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. Am J Gastroenterol</article-title>. <volume>102</volume>: <fpage>2181</fpage>&#x02013;<lpage>2188</lpage>.</mixed-citation></ref><ref id="pone.0087773-Fried1"><label>11</label><mixed-citation publication-type="journal">
<name><surname>Fried</surname><given-names>MW</given-names></name>, <name><surname>Shiffman</surname><given-names>ML</given-names></name>, <name><surname>Reddy</surname><given-names>KR</given-names></name>, <name><surname>Smith</surname><given-names>C</given-names></name>, <name><surname>Marinos</surname><given-names>G</given-names></name>, <etal>et al</etal> (<year>2002</year>) <article-title>Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection</article-title>. <source>N Engl J Med</source>
<volume>347</volume>: <fpage>975</fpage>&#x02013;<lpage>982</lpage>.<pub-id pub-id-type="pmid">12324553</pub-id></mixed-citation></ref><ref id="pone.0087773-Ferrari1"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Ferrari</surname><given-names>E</given-names></name>, <name><surname>He</surname><given-names>Z</given-names></name>, <name><surname>Palermo</surname><given-names>RE</given-names></name>, <name><surname>Huang</surname><given-names>HC</given-names></name> (<year>2008</year>) <article-title>Hepatitis C virus NS5B polymerase exhibits distinct nucleotide requirements for initiation and elongation</article-title>. <source>J Biol Chem</source>
<volume>283</volume>: <fpage>33893</fpage>&#x02013;<lpage>33901</lpage>.<pub-id pub-id-type="pmid">18840605</pub-id></mixed-citation></ref><ref id="pone.0087773-Young1"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Young</surname><given-names>KC</given-names></name>, <name><surname>Lindsay</surname><given-names>KL</given-names></name>, <name><surname>Lee</surname><given-names>KJ</given-names></name>, <name><surname>Liu</surname><given-names>WC</given-names></name>, <name><surname>He</surname><given-names>JW</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy</article-title>. <source>Hepatology</source>
<volume>38</volume>: <fpage>869</fpage>&#x02013;<lpage>878</lpage>.<pub-id pub-id-type="pmid">14512874</pub-id></mixed-citation></ref><ref id="pone.0087773-Cheney1"><label>14</label><mixed-citation publication-type="journal">
<name><surname>Cheney</surname><given-names>IW</given-names></name>, <name><surname>Naim</surname><given-names>S</given-names></name>, <name><surname>Lai</surname><given-names>VC</given-names></name>, <name><surname>Dempsey</surname><given-names>S</given-names></name>, <name><surname>Bellows</surname><given-names>D</given-names></name>, <etal>et al</etal> (<year>2002</year>) <article-title>Mutations in NS5B polymerase of hepatitis C virus: impacts on in vitro enzymatic activity and viral RNA replication in the subgenomic replicon cell culture</article-title>. <source>Virology</source>
<volume>297</volume>: <fpage>298</fpage>&#x02013;<lpage>306</lpage>.<pub-id pub-id-type="pmid">12083828</pub-id></mixed-citation></ref><ref id="pone.0087773-Hamano1"><label>15</label><mixed-citation publication-type="journal">
<name><surname>Hamano</surname><given-names>K</given-names></name>, <name><surname>Sakamoto</surname><given-names>N</given-names></name>, <name><surname>Enomoto</surname><given-names>N</given-names></name>, <name><surname>Izumi</surname><given-names>N</given-names></name>, <name><surname>Asahina</surname><given-names>Y</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon-alpha plus ribavirin combination therapy</article-title>. <source>Journal of Gastroenterology and Hepatology</source>
<volume>20</volume>: <fpage>1401</fpage>&#x02013;<lpage>1409</lpage>.<pub-id pub-id-type="pmid">16105128</pub-id></mixed-citation></ref><ref id="pone.0087773-Watanabe1"><label>16</label><mixed-citation publication-type="journal">
<name><surname>Watanabe</surname><given-names>K</given-names></name>, <name><surname>Yoshioka</surname><given-names>K</given-names></name>, <name><surname>Yano</surname><given-names>M</given-names></name>, <name><surname>Ishigami</surname><given-names>M</given-names></name>, <name><surname>Ukai</surname><given-names>K</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Mutations in the nonstructural region 5B of hepatitis C virus genotype 1b: Their relation to viral load, response to interferon, and the nonstructural region 5A</article-title>. <source>Journal of Medical Virology</source>
<volume>75</volume>: <fpage>504</fpage>&#x02013;<lpage>512</lpage>.<pub-id pub-id-type="pmid">15714488</pub-id></mixed-citation></ref><ref id="pone.0087773-Mo1"><label>17</label><mixed-citation publication-type="journal">
<name><surname>Mo</surname><given-names>H</given-names></name>, <name><surname>Lu</surname><given-names>L</given-names></name>, <name><surname>Pilot-Matias</surname><given-names>T</given-names></name>, <name><surname>Pithawalla</surname><given-names>R</given-names></name>, <name><surname>Mondal</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro</article-title>. <source>Antimicrob Agents Chemother</source>
<volume>49</volume>: <fpage>4305</fpage>&#x02013;<lpage>4314</lpage>.<pub-id pub-id-type="pmid">16189112</pub-id></mixed-citation></ref><ref id="pone.0087773-Plaza1"><label>18</label><mixed-citation publication-type="journal">
<name><surname>Plaza</surname><given-names>Z</given-names></name>, <name><surname>Soriano</surname><given-names>V</given-names></name>, <name><surname>Gonzalez</surname><given-names>MD</given-names></name>, <name><surname>Di Lello</surname><given-names>FA</given-names></name>, <name><surname>Macias</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV/HCV co-infected patients</article-title>. <source>Journal of Antimicrobial Chemotherapy</source>
<volume>66</volume>: <fpage>2838</fpage>&#x02013;<lpage>2842</lpage>.<pub-id pub-id-type="pmid">21954459</pub-id></mixed-citation></ref><ref id="pone.0087773-Blackard1"><label>19</label><mixed-citation publication-type="journal">
<name><surname>Blackard</surname><given-names>JT</given-names></name>, <name><surname>Ma</surname><given-names>G</given-names></name>, <name><surname>Limketkai</surname><given-names>BN</given-names></name>, <name><surname>Welge</surname><given-names>JA</given-names></name>, <name><surname>Dryer</surname><given-names>PD</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Variability of the polymerase gene (NS5B) in hepatitis C virus-infected women</article-title>. <source>J Clin Microbiol</source>
<volume>48</volume>: <fpage>4256</fpage>&#x02013;<lpage>4259</lpage>.<pub-id pub-id-type="pmid">20810773</pub-id></mixed-citation></ref><ref id="pone.0087773-Yan1"><label>20</label><mixed-citation publication-type="journal">
<name><surname>Yan</surname><given-names>KK</given-names></name>, <name><surname>Guirgis</surname><given-names>M</given-names></name>, <name><surname>Dinh</surname><given-names>T</given-names></name>, <name><surname>George</surname><given-names>J</given-names></name>, <name><surname>Dev</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Treatment responses in Asians and Caucasians with chronic hepatitis C infection</article-title>. <source>World J Gastroenterol</source>
<volume>14</volume>: <fpage>3416</fpage>&#x02013;<lpage>3420</lpage>.<pub-id pub-id-type="pmid">18528940</pub-id></mixed-citation></ref><ref id="pone.0087773-Heo1"><label>21</label><mixed-citation publication-type="journal">
<name><surname>Heo</surname><given-names>NY</given-names></name>, <name><surname>Lim</surname><given-names>YS</given-names></name>, <name><surname>Lee</surname><given-names>HC</given-names></name>, <name><surname>Lee</surname><given-names>YS</given-names></name>, <name><surname>Kim</surname><given-names>KM</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice</article-title>. <source>Clin Mol Hepatol</source>
<volume>19</volume>: <fpage>60</fpage>&#x02013;<lpage>69</lpage>.<pub-id pub-id-type="pmid">23593611</pub-id></mixed-citation></ref><ref id="pone.0087773-Lyoo1"><label>22</label><mixed-citation publication-type="journal">
<name><surname>Lyoo</surname><given-names>K</given-names></name>, <name><surname>Song</surname><given-names>MJ</given-names></name>, <name><surname>Hur</surname><given-names>W</given-names></name>, <name><surname>Choi</surname><given-names>JE</given-names></name>, <name><surname>Hong</surname><given-names>SW</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin</article-title>. <source>J Clin Virol</source>
<volume>52</volume>: <fpage>363</fpage>&#x02013;<lpage>366</lpage>.<pub-id pub-id-type="pmid">21907615</pub-id></mixed-citation></ref><ref id="pone.0087773-Thomas1"><label>23</label><mixed-citation publication-type="journal">
<name><surname>Thomas</surname><given-names>DL</given-names></name>, <name><surname>Thio</surname><given-names>CL</given-names></name>, <name><surname>Martin</surname><given-names>MP</given-names></name>, <name><surname>Qi</surname><given-names>Y</given-names></name>, <name><surname>Ge</surname><given-names>D</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Genetic variation in IL28B and spontaneous clearance of hepatitis C virus</article-title>. <source>Nature</source>
<volume>461</volume>: <fpage>798</fpage>&#x02013;<lpage>U752</lpage>.<pub-id pub-id-type="pmid">19759533</pub-id></mixed-citation></ref><ref id="pone.0087773-Ge1"><label>24</label><mixed-citation publication-type="journal">
<name><surname>Ge</surname><given-names>D</given-names></name>, <name><surname>Fellay</surname><given-names>J</given-names></name>, <name><surname>Thompson</surname><given-names>AJ</given-names></name>, <name><surname>Simon</surname><given-names>JS</given-names></name>, <name><surname>Shianna</surname><given-names>KV</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance</article-title>. <source>Nature</source>
<volume>461</volume>: <fpage>399</fpage>&#x02013;<lpage>401</lpage>.<pub-id pub-id-type="pmid">19684573</pub-id></mixed-citation></ref><ref id="pone.0087773-Puoti1"><label>25</label><mixed-citation publication-type="journal">
<name><surname>Puoti</surname><given-names>C</given-names></name> (<year>2004</year>) <article-title>HCV carriers with persistently normal ALT Levels: not too much healthy, not true patients</article-title>. <source>Rom J Gastroenterol</source>
<volume>13</volume>: <fpage>329</fpage>&#x02013;<lpage>332</lpage>.<pub-id pub-id-type="pmid">15624031</pub-id></mixed-citation></ref><ref id="pone.0087773-Sinn1"><label>26</label><mixed-citation publication-type="journal">
<name><surname>Sinn</surname><given-names>DH</given-names></name>, <name><surname>Gwak</surname><given-names>GY</given-names></name>, <name><surname>Shin</surname><given-names>JU</given-names></name>, <name><surname>Choi</surname><given-names>MS</given-names></name>, <name><surname>Lee</surname><given-names>JH</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Disease progression in chronic hepatitis C patients with normal alanine aminotransferase levels</article-title>. <source>World J Gastroenterol</source>
<volume>19</volume>: <fpage>2256</fpage>&#x02013;<lpage>2261</lpage>.<pub-id pub-id-type="pmid">23599653</pub-id></mixed-citation></ref><ref id="pone.0087773-Lok1"><label>27</label><mixed-citation publication-type="journal">
<name><surname>Lok</surname><given-names>AS</given-names></name>, <name><surname>McMahon</surname><given-names>BJ</given-names></name> (<year>2007</year>) <article-title>Chronic hepatitis B</article-title>. <source>Hepatology</source>
<volume>45</volume>: <fpage>507</fpage>&#x02013;<lpage>539</lpage>.<pub-id pub-id-type="pmid">17256718</pub-id></mixed-citation></ref><ref id="pone.0087773-Bruix1"><label>28</label><mixed-citation publication-type="journal">
<name><surname>Bruix</surname><given-names>J</given-names></name>, <name><surname>Castells</surname><given-names>A</given-names></name>, <name><surname>Bosch</surname><given-names>J</given-names></name>, <name><surname>Feu</surname><given-names>F</given-names></name>, <name><surname>Fuster</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>1996</year>) <article-title>Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure</article-title>. <source>Gastroenterology</source>
<volume>111</volume>: <fpage>1018</fpage>&#x02013;<lpage>1022</lpage>.<pub-id pub-id-type="pmid">8831597</pub-id></mixed-citation></ref><ref id="pone.0087773-DiLelio1"><label>29</label><mixed-citation publication-type="journal">
<name><surname>Di Lelio</surname><given-names>A</given-names></name>, <name><surname>Cestari</surname><given-names>C</given-names></name>, <name><surname>Lomazzi</surname><given-names>A</given-names></name>, <name><surname>Beretta</surname><given-names>L</given-names></name> (<year>1989</year>) <article-title>Cirrhosis: diagnosis with sonographic study of the liver surface</article-title>. <source>Radiology</source>
<volume>172</volume>: <fpage>389</fpage>&#x02013;<lpage>392</lpage>.<pub-id pub-id-type="pmid">2526349</pub-id></mixed-citation></ref><ref id="pone.0087773-Bruguera1"><label>30</label><mixed-citation publication-type="journal">
<name><surname>Bruguera</surname><given-names>M</given-names></name>, <name><surname>Bordas</surname><given-names>JM</given-names></name>, <name><surname>Mas</surname><given-names>P</given-names></name>, <name><surname>Rodes</surname><given-names>J</given-names></name> (<year>1974</year>) <article-title>A comparison of the accuracy of peritoneoscopy and liver biopsy in the diagnosis of cirrhosis</article-title>. <source>Gut</source>
<volume>15</volume>: <fpage>799</fpage>&#x02013;<lpage>800</lpage>.<pub-id pub-id-type="pmid">4279817</pub-id></mixed-citation></ref><ref id="pone.0087773-Bruix2"><label>31</label><mixed-citation publication-type="journal">
<name><surname>Bruix</surname><given-names>J</given-names></name>, <name><surname>Sherman</surname><given-names>M</given-names></name>, <name><surname>Llovet</surname><given-names>JM</given-names></name>, <name><surname>Beaugrand</surname><given-names>M</given-names></name>, <name><surname>Lencioni</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2001</year>) <article-title>Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver</article-title>. <source>J Hepatol</source>
<volume>35</volume>: <fpage>421</fpage>&#x02013;<lpage>430</lpage>.<pub-id pub-id-type="pmid">11592607</pub-id></mixed-citation></ref><ref id="pone.0087773-Nakatani1"><label>32</label><mixed-citation publication-type="journal">
<name><surname>Nakatani</surname><given-names>SM</given-names></name>, <name><surname>Santos</surname><given-names>CA</given-names></name>, <name><surname>Riediger</surname><given-names>IN</given-names></name>, <name><surname>Krieger</surname><given-names>MA</given-names></name>, <name><surname>Duarte</surname><given-names>CA</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Development of hepatitis C virus genotyping by real-time PCR based on the NS5B region</article-title>. <source>PLoS One</source>
<volume>5</volume>: <fpage>e10150</fpage>.<pub-id pub-id-type="pmid">20405017</pub-id></mixed-citation></ref><ref id="pone.0087773-Pawlotsky1"><label>33</label><mixed-citation publication-type="journal">
<name><surname>Pawlotsky</surname><given-names>JM</given-names></name> (<year>2002</year>) <article-title>Use and interpretation of virological tests for hepatitis C. Hepatology</article-title>. <volume>36</volume>: <fpage>S65</fpage>&#x02013;<lpage>73</lpage>.</mixed-citation></ref><ref id="pone.0087773-vanAsten1"><label>34</label><mixed-citation publication-type="journal">
<name><surname>van Asten</surname><given-names>L</given-names></name>, <name><surname>Verhaest</surname><given-names>I</given-names></name>, <name><surname>Lamzira</surname><given-names>S</given-names></name>, <name><surname>Hernandez-Aguado</surname><given-names>I</given-names></name>, <name><surname>Zangerle</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Spread of hepatitis C virus among European injection drug users infected with HIV: A phylogenetic analysis</article-title>. <source>Journal of Infectious Diseases</source>
<volume>189</volume>: <fpage>292</fpage>&#x02013;<lpage>302</lpage>.<pub-id pub-id-type="pmid">14722895</pub-id></mixed-citation></ref><ref id="pone.0087773-Cuevas1"><label>35</label><mixed-citation publication-type="journal">
<name><surname>Cuevas</surname><given-names>JM</given-names></name>, <name><surname>Gonzalez-Candelas</surname><given-names>F</given-names></name>, <name><surname>Moya</surname><given-names>A</given-names></name>, <name><surname>Sanjuan</surname><given-names>R</given-names></name> (<year>2009</year>) <article-title>Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo</article-title>. <source>J Virol</source>
<volume>83</volume>: <fpage>5760</fpage>&#x02013;<lpage>5764</lpage>.<pub-id pub-id-type="pmid">19321623</pub-id></mixed-citation></ref><ref id="pone.0087773-Uzicanin1"><label>36</label><mixed-citation publication-type="journal">
<name><surname>Uzicanin</surname><given-names>S</given-names></name>, <name><surname>Hu</surname><given-names>YW</given-names></name>, <name><surname>Alsousi</surname><given-names>H</given-names></name>, <name><surname>Pelchat</surname><given-names>M</given-names></name>, <name><surname>Rocheleau</surname><given-names>L</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Hepatitis C virus: the role of molecular mimicry in response to interferon treatment</article-title>. <source>J Med Virol</source>
<volume>84</volume>: <fpage>1571</fpage>&#x02013;<lpage>1585</lpage>.<pub-id pub-id-type="pmid">22930505</pub-id></mixed-citation></ref><ref id="pone.0087773-Ruhl1"><label>37</label><mixed-citation publication-type="journal">
<name><surname>Ruhl</surname><given-names>M</given-names></name>, <name><surname>Knuschke</surname><given-names>T</given-names></name>, <name><surname>Schewior</surname><given-names>K</given-names></name>, <name><surname>Glavinic</surname><given-names>L</given-names></name>, <name><surname>Neumann-Haefelin</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>CD8(+) T-Cell Response Promotes Evolution of Hepatitis C Virus Nonstructural Proteins</article-title>. <source>Gastroenterology</source>
<volume>140</volume>: <fpage>2064</fpage>&#x02013;<lpage>2073</lpage>.<pub-id pub-id-type="pmid">21376049</pub-id></mixed-citation></ref><ref id="pone.0087773-Hang1"><label>38</label><mixed-citation publication-type="journal">
<name><surname>Hang</surname><given-names>JQ</given-names></name>, <name><surname>Yang</surname><given-names>Y</given-names></name>, <name><surname>Harris</surname><given-names>SF</given-names></name>, <name><surname>Leveque</surname><given-names>V</given-names></name>, <name><surname>Whittington</surname><given-names>HJ</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus</article-title>. <source>J Biol Chem</source>
<volume>284</volume>: <fpage>15517</fpage>&#x02013;<lpage>15529</lpage>.<pub-id pub-id-type="pmid">19246450</pub-id></mixed-citation></ref><ref id="pone.0087773-Ludmerer1"><label>39</label><mixed-citation publication-type="journal">
<name><surname>Ludmerer</surname><given-names>SW</given-names></name>, <name><surname>Graham</surname><given-names>DJ</given-names></name>, <name><surname>Boots</surname><given-names>E</given-names></name>, <name><surname>Murray</surname><given-names>EM</given-names></name>, <name><surname>Simcoe</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay</article-title>. <source>Antimicrob Agents Chemother</source>
<volume>49</volume>: <fpage>2059</fpage>&#x02013;<lpage>2069</lpage>.<pub-id pub-id-type="pmid">15855532</pub-id></mixed-citation></ref><ref id="pone.0087773-Saitou1"><label>40</label><mixed-citation publication-type="journal">
<name><surname>Saitou</surname><given-names>N</given-names></name>, <name><surname>Nei</surname><given-names>M</given-names></name> (<year>1987</year>) <article-title>The neighbor-joining method: a new method for reconstructing phylogenetic trees</article-title>. <source>Mol Biol Evol</source>
<volume>4</volume>: <fpage>406</fpage>&#x02013;<lpage>425</lpage>.<pub-id pub-id-type="pmid">3447015</pub-id></mixed-citation></ref><ref id="pone.0087773-Tamura1"><label>41</label><mixed-citation publication-type="journal">
<name><surname>Tamura</surname><given-names>K</given-names></name>, <name><surname>Dudley</surname><given-names>J</given-names></name>, <name><surname>Nei</surname><given-names>M</given-names></name>, <name><surname>Kumar</surname><given-names>S</given-names></name> (<year>2007</year>) <article-title>MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0</article-title>. <source>Mol Biol Evol</source>
<volume>24</volume>: <fpage>1596</fpage>&#x02013;<lpage>1599</lpage>.<pub-id pub-id-type="pmid">17488738</pub-id></mixed-citation></ref><ref id="pone.0087773-Mazumder1"><label>42</label><mixed-citation publication-type="journal">
<name><surname>Mazumder</surname><given-names>R</given-names></name>, <name><surname>Hu</surname><given-names>ZZ</given-names></name>, <name><surname>Vinayaka</surname><given-names>CR</given-names></name>, <name><surname>Sagripanti</surname><given-names>JL</given-names></name>, <name><surname>Frost</surname><given-names>SD</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Computational analysis and identification of amino acid sites in dengue E proteins relevant to development of diagnostics and vaccines</article-title>. <source>Virus Genes</source>
<volume>35</volume>: <fpage>175</fpage>&#x02013;<lpage>186</lpage>.<pub-id pub-id-type="pmid">17508277</pub-id></mixed-citation></ref><ref id="pone.0087773-Chang1"><label>43</label><mixed-citation publication-type="journal">
<name><surname>Chang</surname><given-names>KM</given-names></name>, <name><surname>Thimme</surname><given-names>R</given-names></name>, <name><surname>Melpolder</surname><given-names>JJ</given-names></name>, <name><surname>Oldach</surname><given-names>D</given-names></name>, <name><surname>Pemberton</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2001</year>) <article-title>Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection</article-title>. <source>Hepatology</source>
<volume>33</volume>: <fpage>267</fpage>&#x02013;<lpage>276</lpage>.<pub-id pub-id-type="pmid">11124845</pub-id></mixed-citation></ref><ref id="pone.0087773-NeumannHaefelin1"><label>44</label><mixed-citation publication-type="journal">
<name><surname>Neumann-Haefelin</surname><given-names>C</given-names></name>, <name><surname>Oniangue-Ndza</surname><given-names>C</given-names></name>, <name><surname>Kuntzen</surname><given-names>T</given-names></name>, <name><surname>Schmidt</surname><given-names>J</given-names></name>, <name><surname>Nitschke</surname><given-names>K</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Human Leukocyte Antigen B27 Selects for Rare Escape Mutations That Significantly Impair Hepatitis C Virus Replication and Require Compensatory Mutations</article-title>. <source>Hepatology</source>
<volume>54</volume>: <fpage>1157</fpage>&#x02013;<lpage>1166</lpage>.<pub-id pub-id-type="pmid">22006856</pub-id></mixed-citation></ref><ref id="pone.0087773-Kobayashi1"><label>45</label><mixed-citation publication-type="journal">
<name><surname>Kobayashi</surname><given-names>K</given-names></name>, <name><surname>Ishii</surname><given-names>M</given-names></name>, <name><surname>Shiina</surname><given-names>M</given-names></name>, <name><surname>Ueno</surname><given-names>Y</given-names></name>, <name><surname>Kondo</surname><given-names>Y</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Interferon-gamma is produced by CD8(+) T cells in response to HLA-A24-restricted hepatitis C virus epitopes after sustained virus loss</article-title>. <source>Clinical and Experimental Immunology</source>
<volume>141</volume>: <fpage>81</fpage>&#x02013;<lpage>88</lpage>.<pub-id pub-id-type="pmid">15958073</pub-id></mixed-citation></ref><ref id="pone.0087773-Oh1"><label>46</label><mixed-citation publication-type="journal">
<name><surname>Oh</surname><given-names>DJ</given-names></name>, <name><surname>Park</surname><given-names>YM</given-names></name>, <name><surname>Seo</surname><given-names>YI</given-names></name>, <name><surname>Lee</surname><given-names>JS</given-names></name>, <name><surname>Lee</surname><given-names>JY</given-names></name> (<year>2012</year>) <article-title>Prevalence of Hepatitis C Virus Infections and Distribution of Hepatitis C Virus Genotypes among Korean Blood Donors</article-title>. <source>Annals of Laboratory Medicine</source>
<volume>32</volume>: <fpage>210</fpage>&#x02013;<lpage>215</lpage>.<pub-id pub-id-type="pmid">22563557</pub-id></mixed-citation></ref><ref id="pone.0087773-NeumannHaefelin2"><label>47</label><mixed-citation publication-type="journal">
<name><surname>Neumann-Haefelin</surname><given-names>C</given-names></name>, <name><surname>McKiernan</surname><given-names>S</given-names></name>, <name><surname>Ward</surname><given-names>S</given-names></name>, <name><surname>Viazov</surname><given-names>S</given-names></name>, <name><surname>Spangenberg</surname><given-names>HC</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution</article-title>. <source>Hepatology</source>
<volume>43</volume>: <fpage>563</fpage>&#x02013;<lpage>572</lpage>.<pub-id pub-id-type="pmid">16496339</pub-id></mixed-citation></ref><ref id="pone.0087773-Jaspe1"><label>48</label><mixed-citation publication-type="other">Jaspe RC, Sulbaran YF, Sulbaran MZ, Loureiro CL, Rangel HR, et al. (2012) Prevalence of amino acid mutations in hepatitis C virus core and NS5B regions among Venezuelan viral isolates and comparison with worldwide isolates. Virology Journal 9.</mixed-citation></ref><ref id="pone.0087773-Thio1"><label>49</label><mixed-citation publication-type="journal">
<name><surname>Thio</surname><given-names>CL</given-names></name>, <name><surname>Thomas</surname><given-names>DL</given-names></name>, <name><surname>Goedert</surname><given-names>JJ</given-names></name>, <name><surname>Vlahov</surname><given-names>D</given-names></name>, <name><surname>Nelson</surname><given-names>KE</given-names></name>, <etal>et al</etal> (<year>2001</year>) <article-title>Racial differences in HLA class II associations with hepatitis C virus outcomes</article-title>. <source>J Infect Dis</source>
<volume>184</volume>: <fpage>16</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">11398104</pub-id></mixed-citation></ref><ref id="pone.0087773-SchulzeZurWiesch1"><label>50</label><mixed-citation publication-type="journal">
<name><surname>Schulze Zur Wiesch</surname><given-names>J</given-names></name>, <name><surname>Ciuffreda</surname><given-names>D</given-names></name>, <name><surname>Lewis-Ximenez</surname><given-names>L</given-names></name>, <name><surname>Kasprowicz</surname><given-names>V</given-names></name>, <name><surname>Nolan</surname><given-names>BE</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence</article-title>. <source>J Exp Med</source>
<volume>209</volume>: <fpage>61</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">22213804</pub-id></mixed-citation></ref><ref id="pone.0087773-Grakoui1"><label>51</label><mixed-citation publication-type="journal">
<name><surname>Grakoui</surname><given-names>A</given-names></name>, <name><surname>Shoukry</surname><given-names>NH</given-names></name>, <name><surname>Woollard</surname><given-names>DJ</given-names></name>, <name><surname>Han</surname><given-names>JH</given-names></name>, <name><surname>Hanson</surname><given-names>HL</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>HCV persistence and immune evasion in the absence of memory T cell help</article-title>. <source>Science</source>
<volume>302</volume>: <fpage>659</fpage>&#x02013;<lpage>662</lpage>.<pub-id pub-id-type="pmid">14576438</pub-id></mixed-citation></ref><ref id="pone.0087773-Chung1"><label>52</label><mixed-citation publication-type="journal">
<name><surname>Chung</surname><given-names>HY</given-names></name>, <name><surname>Yoon</surname><given-names>JA</given-names></name>, <name><surname>Han</surname><given-names>BY</given-names></name>, <name><surname>Song</surname><given-names>EY</given-names></name>, <name><surname>Park</surname><given-names>MH</given-names></name> (<year>2010</year>) <article-title>[Allelic and haplotypic diversity of HLA-A, -B, -C, and -DRB1 genes in Koreans defined by high-resolution DNA typing]</article-title>. <source>Korean J Lab Med</source>
<volume>30</volume>: <fpage>685</fpage>&#x02013;<lpage>696</lpage>.<pub-id pub-id-type="pmid">21157157</pub-id></mixed-citation></ref><ref id="pone.0087773-Minton1"><label>53</label><mixed-citation publication-type="journal">
<name><surname>Minton</surname><given-names>EJ</given-names></name>, <name><surname>Smillie</surname><given-names>D</given-names></name>, <name><surname>Neal</surname><given-names>KR</given-names></name>, <name><surname>Irving</surname><given-names>WL</given-names></name>, <name><surname>Underwood</surname><given-names>JC</given-names></name>, <etal>et al</etal> (<year>1998</year>) <article-title>Association between MHC class II alleles and clearance of circulating hepatitis C virus. Members of the Trent Hepatitis C Virus Study Group</article-title>. <source>J Infect Dis</source>
<volume>178</volume>: <fpage>39</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">9652421</pub-id></mixed-citation></ref><ref id="pone.0087773-Kuzushita1"><label>54</label><mixed-citation publication-type="journal">
<name><surname>Kuzushita</surname><given-names>N</given-names></name>, <name><surname>Hayashi</surname><given-names>N</given-names></name>, <name><surname>Moribe</surname><given-names>T</given-names></name>, <name><surname>Katayama</surname><given-names>K</given-names></name>, <name><surname>Kanto</surname><given-names>T</given-names></name>, <etal>et al</etal> (<year>1998</year>) <article-title>Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus</article-title>. <source>Hepatology</source>
<volume>27</volume>: <fpage>240</fpage>&#x02013;<lpage>244</lpage>.<pub-id pub-id-type="pmid">9425943</pub-id></mixed-citation></ref><ref id="pone.0087773-Ali1"><label>55</label><mixed-citation publication-type="journal">
<name><surname>Ali</surname><given-names>L</given-names></name>, <name><surname>Mansoor</surname><given-names>A</given-names></name>, <name><surname>Ahmad</surname><given-names>N</given-names></name>, <name><surname>Siddiqi</surname><given-names>S</given-names></name>, <name><surname>Mazhar</surname><given-names>K</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Patient HLA-DRB1* and -DQB1* allele and haplotype association with hepatitis C virus persistence and clearance</article-title>. <source>J Gen Virol</source>
<volume>91</volume>: <fpage>1931</fpage>&#x02013;<lpage>1938</lpage>.<pub-id pub-id-type="pmid">20392899</pub-id></mixed-citation></ref><ref id="pone.0087773-Kim1"><label>56</label><mixed-citation publication-type="other">Kim DW, Lee SA, Hwang ES, Kook YH, Kim BJ (2012) Naturally Occurring Precore/Core Region Mutations of Hepatitis B Virus Genotype C Related to Hepatocellular Carcinoma. Plos One 7.</mixed-citation></ref><ref id="pone.0087773-NeumannHaefelin3"><label>57</label><mixed-citation publication-type="journal">
<name><surname>Neumann-Haefelin</surname><given-names>C</given-names></name>, <name><surname>Timm</surname><given-names>J</given-names></name>, <name><surname>Schmidt</surname><given-names>J</given-names></name>, <name><surname>Kersting</surname><given-names>N</given-names></name>, <name><surname>Fitzmaurice</surname><given-names>K</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Protective Effect of Human Leukocyte Antigen B27 in Hepatitis C Virus Infection Requires the Presence of a Genotype-Specific Immunodominant CD8+ T-Cell Epitope</article-title>. <source>Hepatology</source>
<volume>51</volume>: <fpage>54</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">20034048</pub-id></mixed-citation></ref><ref id="pone.0087773-Liu2"><label>58</label><mixed-citation publication-type="journal">
<name><surname>Liu</surname><given-names>Z</given-names></name>, <name><surname>Robida</surname><given-names>JM</given-names></name>, <name><surname>Chinnaswamy</surname><given-names>S</given-names></name>, <name><surname>Yi</surname><given-names>GH</given-names></name>, <name><surname>Robotham</surname><given-names>JM</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Mutations in the Hepatitis C Virus Polymerase that Increase RNA Binding Can Confer Resistance to Cyclosporine A. Hepatology</article-title>. <volume>50</volume>: <fpage>25</fpage>&#x02013;<lpage>33</lpage>.</mixed-citation></ref></ref-list></back></article>